|
|
News Breaks | | | | January 30, 2013 | | 09:04 EDT |  | STJ | St. Jude Medical enrolls first patient in EnlighHTN II trial for hypertension
St. Jude Medical enrolled the first patient in the EnligHTN II trial. This post-market clinical study will further evaluate the safety and efficacy of the EnligHTN Renal Denervation System in patients with uncontrolled hypertension. The EnligHTN II trial expands upon the research conducted in the EnligHTN I trial, which demonstrated that patients with drug-resistant hypertension treated with the St. Jude Medical EnligHTN system had a rapid and sustained drop in blood pressure. The EnligHTN II study aims to broaden this scope by evaluating the mean reduction in systolic blood pressure at six months across all enrolled patients post renal denervation and within sub-groups with varying degrees of kidney functionality. The study will enroll approximately 500 patients | |
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| June 11, 2013 | | 16:08 EDT | | STJ | FDA approves St. Jude Medical devices with new safety features
St. Jude Medical announced FDA approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery. | | | June 10, 2013 | | 12:22 EDT |  | STJ | St. Jude's Durata backed by doctor who found Riata defect, Bloomberg says
 Subscribe for More Information | | | June 7, 2013 | | 11:05 EDT | | STJ | St. Jude invests $40M in Spinal Modulation, gets exclusive option to acquire
St. Jude Medical and privately-held Spinal Modulation announced that they have entered into a series of agreements under which St. Jude Medical made a $40M equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain. The agreement provides St. Jude Medical with an exclusive option to distribute the Axium Neurostimulator System, developed and manufactured by Spinal Modulation, in international markets where it is approved for sale. Additionally, St. Jude Medical will have the exclusive option to acquire the company for up to $300M plus certain revenue-based milestones following U.S. commercialization. | |
|
|
|
|
|
|
